| Basics |
Fate Therapeutics, Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
|
| IPO Date: |
October 1, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$122.66M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.59 | 3.52%
|
| Avg Daily Range (30 D): |
$0.08 | 7.92%
|
| Avg Daily Range (90 D): |
$0.06 | 5.53%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.85M |
| Avg Daily Volume (30 D): |
1.91M |
| Avg Daily Volume (90 D): |
1.95M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
281 |
| Avg Trade Size (Sh.) (90 D): |
300 |
| Institutional Trades |
| Total Inst.Trades: |
3,464 |
| Avg Inst. Trade: |
$2.74M |
| Avg Inst. Trade (30 D): |
$.85M |
| Avg Inst. Trade (90 D): |
$1.42M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.83M |
| Avg Closing Trade (30 D): |
$.64M |
| Avg Closing Trade (90 D): |
$.64M |
| Avg Closing Volume: |
204.45K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-1.5
|
$-.32
|
$-.45
|
|
Diluted EPS
|
$-1.5
|
$-.32
|
$-.45
|
|
Revenue
|
$ 13.34M
|
$ 1.63M
|
$ 1.86M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -175.88M
|
$ -37.62M
|
$ -52.15M
|
|
Operating Income / Loss
|
$ -200.49M
|
$ -41.28M
|
$ -61.75M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -90.22M
|
$ M
|
$ -1.85M
|
|
PE Ratio
|
|
|
|
|
